Spastic paraparesis

Common Name(s)

Spastic paraparesis

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Spastic paraparesis" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Spastic paraparesis" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Spastic paraparesis" returned 168 free, full-text research articles on human participants. First 3 results:

Common γ-chain blocking peptide reduces in vitro immune activation markers in HTLV-1-associated myelopathy/tropical spastic paraparesis.
 

Author(s): Raya Massoud, Yoshimi Enose-Akahata, Yutaka Tagaya, Nazli Azimi, Asjad Basheer, Steven Jacobson

Journal: Proc. Natl. Acad. Sci. U.S.A.. 2015 Sep;112(35):11030-5.

 

Human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a progressive inflammatory myelopathy occurring in a subset of HTLV-1-infected individuals. Despite advances in understanding its immunopathogenesis, an effective treatment ...

Last Updated: 2 Sep 2015

Go To URL
Clinical presentation of axial myopathy in two siblings with HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP).
 

Author(s): Eiji Matsuura, Akiko Yoshimura, Satoshi Nozuma, Itsuro Higuchi, Ryuji Kubota, Hiroshi Takashima

Journal:

 

The clinical features of myositis related with Human T-cell leukemia virus type 1 (HTLV-1) remains unclear despite epidemiological studies suggesting inflammatory myopathy associated with the virus.

Last Updated: 18 Apr 2015

Go To URL
High IFN-γ/IL-10 expression ratio and increased frequency of persistent human T-cell lymphotropic virus type 1-infected clones are associated with human T-cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis development.
 

Author(s): Otávio M Espíndola, Luã C Oliveira, Priscilla M S Ferreira, Ana Claudia C B Leite, Marco Antonio S D Lima, Maria José Andrada-Serpa

Journal: Intervirology. 2015 ;58(2):106-14.

 

Human T-cell lymphotropic virus type 1 (HTLV-1) is a retrovirus that causes a persistent infection, and only 0.5-5% of infected individuals will develop HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Therefore, we investigated parameters to discriminate HTLV-1 ...

Last Updated: 2 Apr 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Spastic paraparesis" returned 13 free, full-text review articles on human participants. First 3 results:

[Tropical spastic paraparesis: a report of a new case in Spain].
 

Author(s): Luciana Midaglia, Antonio Pato-Pato, Iria Rodriguez-Constenla, Eloísa Santos-Armentia, Iciar Cimas-Hernando, María Lopez-Fernandez, Delicias Munoz-Garcia, Candelas Valeiras-Munoz, José R Lorenzo-Gonzalez

Journal: Rev Neurol. 2014 Jun;58(12):573-5.

 

Last Updated: 11 Jun 2014

Go To URL
Treatment of HTLV-I-associated myelopathy/tropical spastic paraparesis: toward rational targeted therapy.
 

Author(s): Unsong Oh, Steven Jacobson

Journal: Neurol Clin. 2008 Aug;26(3):781-97, ix-x.

 

The treatment of HAM/TSP is a challenge. No agent has shown to significantly modify the long-term disability associated with HAM/TSP. Advances in our understanding of the pathogenesis of HAM/TSP have led to the identification of several biomarkers and therapeutic targets. Clinical ...

Last Updated: 28 Jul 2008

Go To URL
Variable phenotype of Alzheimer's disease with spastic paraparesis.
 

Author(s): Helena Karlstrom, William S Brooks, John B J Kwok, G Anthony Broe, Jillian J Kril, Heather McCann, Glenda M Halliday, Peter R Schofield

Journal: J. Neurochem.. 2008 Feb;104(3):573-83.

 

Pedigrees with familial Alzheimer's disease (AD) show considerable phenotypic variability. Spastic paraparesis (SP), or progressive spasticity of the lower limbs is frequently hereditary and exists either as uncomplicated (paraparesis alone) or complicated (paraparesis and other neurological ...

Last Updated: 17 Jan 2008

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection
 

Status: Not yet recruiting

Condition Summary: HTLV-I Infections; Tropical Spastic Paraparesis

 

Last Updated: 11 Jan 2016

Go to URL
Evaluation of Patients With HAM/TSP
 

Status: Recruiting

Condition Summary: HTLV-I Infection; Tropical Spastic Paraparesis

 

Last Updated: 5 Aug 2015

Go to URL

Last Updated: 17 Feb 2016

Go to URL